Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01227291

SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg

Study With SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With IOP >= 21 mm Hg.

Sponsor: Sylentis, S.A.

Interventions SYL040012

Updated 5 times since 2017 Last updated: Sep 26, 2012 Started: Oct 31, 2010 Primary completion: Mar 31, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Glaucoma and Ocular Hypertension and is currently completed. Sylentis, S.A. leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sylentis, S.A.

Data source: Sylentis, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madrid, Spain
• Pamplona, Spain